MRC quality of life studies using a daily diary card—practical lessons learned from cancer trials (original) (raw)
- Fayers PM, Jones DR. Measuring and analysing quality of life in cancer clinical trials: a review.Stat Med 1983;2: 429–446.
Google Scholar - Bleehen NM, Fayers PM, Girling DJ, Stephens RJ. Survival, adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.Respir Med 1989;83: 51–58.
Google Scholar - Bleehen NM, Fayers PM, Girling DJ, Stephens RJ. Controlled trial of twelve versus six courses of chemotherapy in the treatment of small-cell lung cancer. Report to the Medical Research Council by its Lung Cancer Working Party.Br J Cancer 1989;59: 584–590.
Google Scholar - Fayers PM, Bleehen NM, Girling DJ, Sephens RJ. Assessment of quality of life in small-cell lung cancer using a Daily Diary Card developed by the Medical Research Council Lund Cancer Working Party.Br J Cancer 1991;64: 299–306.
Google Scholar - Bleehen NM, Girling DJ, Fayers PM, et al. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party.Br J Cancer 1991;63: 265–270.
Google Scholar - Bleehen NM, Bolger JJ, Girling DJ, et al. A Medical-Research Council (MRC) randomized trial of palliative radiotherapy with 2 fractions or a single fraction in patients with inoperable non-small-cell lung-cancer (NSCLC) and poor performance status.Br J Cancer 1992;65: 934–941.
Google Scholar - Bleehen NM, Girling DJ, Machin D, Stephens RJ. A randomised trial of three or six courses of etoposide cyclophosphamide methotrexate and vincristine or six courses of etoposide and ifosfamide in small cell lung cancer (SCLC). II: Quality of life. Medical Research Council Lung Cancer Working Party.Br J Cancer 1993;68: 1157–1166.
Google Scholar - Geddes DM, Dones L, Hill E, et al. Quality of life during chemotherapy for small cell lung cancer: assessment and use of a daily card in a randomized trial.Eur J Cancer 1990;26: 484–492.
Google Scholar - Earl HM, Rudd RM, Spiro SG, et al. A randomised trial of planned versus as required chemotherapy in small cell lung cancer: a Cancer Research Campaign trial.Br J Cancer 1991;64: 566–572.
Google Scholar - Lee CR, Nicholson PW, Souhami RL, Deshmukh AA. Patient compliance with oral chemotherapy as assessed by a novel electronic technique.J Clin Oncol 1992;10: 1007–1013.
Google Scholar - de Haes JCJM, van Knippenberg FCE, Neijt JP. Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist.Br J Cancer 1990;62: 1034–1038.
Google Scholar - Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale.Acta Psychiatr Scand 1983;67: 361–370.
Google Scholar - Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology.J Natl Cancer Inst 1993;85: 365–376.
Google Scholar - Medical Research Council. Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Medical Research Council Lung Cancer Working Party.Br J Cancer 1979;40: 1–10.
Google Scholar - Fraser SC, Dobbs HJ, Ebbs SR, et al. Combination or mild single agent chemotherapy for advanced breast cancer? CMF vs epirubicin measuring quality of life.Br J Cancer 1993;67: 402–406.
Google Scholar - Fraser SC, Ramirez AJ, Ebbs SR, et al. A daily diary for quality of life measurement in advanced breast cancer trials.Br J Cancer 1993;67: 341–346.
Google Scholar - Lindley CM, Hirsch JD, O'Neill CV, et al. Quality of life consequences of chemotherapy-induced emesis.Qual Life Res 1992;1: 331–340.
Google Scholar - Archer LNJ, Simpson H. Nigh cough counts and diary card scores in asthma.Arch Dis Child 1985;60: 473–474.
Google Scholar - Machin D, d'Arcangues C, Busca B, et al. Vaginal bleeding patterns—the problem and an example data set.Appl Stoch Models Data Anal 1987;3: 27–35.
Google Scholar - Aaronson NK, Cull A, Kaasa S, Sprangers MAG. The EORTC modular approach to quality-of-life assessment in oncology.Int J Ment Health 1994;23, 75–96.
Google Scholar - Morittu L, Earl HM, Souhami RL, et al. Identification of patients at risk of chemotherapy-induced toxicity.Br J Cancer 1989;59: 801–804.
Google Scholar - Stephens RJ, Girling DJ, Machin D. Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified?Lung Cancer (Netherlands) 1994;1: 259–274.
Google Scholar - Girling DJ, Hopwood P, Ahmedzai S. Assessing quality of life in palliative oncology.Prog Pall Care 1994;2: 80–86.
Google Scholar - Streiner DL, Norman GR.Health Measurement Scales. Oxford: Oxford University Press, 1989.
Google Scholar - Ganz PA, Haskell CM, Figlin RA, et al. Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the Functional Living Index-Cancer.Cancer 1988;61: 849–856.
Google Scholar - Ganz PA, Figlin RA, Haskell CM, et al. Supportive care versus supportive care and combination chemotherapy in metastatic non-small cell lung cancer. Does chemotherapy make a difference?Cancer 1989;63: 1271–1278.
Google Scholar - Zwinderman AH. Statistical analysis of longitudinal quality of life data with missing measurements.Qual Life Res 1992;1: 219–224.
Google Scholar - Cook DJ, Guyatt GH, Juniper EF, et al. Interviewer versus self-administered questionnaires in developing a disease-specific, health-related quality of life instrument for asthma.J Clin Epidemiol 1993;46: 529–534.
Google Scholar - Bergner M, Bobbit RA, Carter WB, Gilson BS. The Sickness Impact Profile: development and final revision of a health status measure.Med Care 1981;19: 787–805.
Google Scholar - Hutchinson TA, Boyd NF, Feinstein AR. Scientific Problems in Clinical Scales, as Demonstrated in the Karnofsky Index of Performance Status.J Chron Dis 1979;32: 661–666.
Google Scholar - Aaronson NK. Quality of life assessment in clinical trials: methodologic issues.Control Clin Trials 1989;10 (Suppl): 195S-208S.
Google Scholar - Olver IN, Matthews JP, Bishop JF, Smith RA. The roles of patient and observer assessments in anti-emetic trials.Eur J Cancer 1994;30A: 1223–1227.
Google Scholar - Osoba D. Lessons learned from measuring health-related quality of life in oncology.J Clin Oncol 1994;12: 608–616.
Google Scholar - de Bruin AF, de Witte LP, Stevens F, Diederiks JP. Sickness Impact Profile: the state of the art of a generic functional status measure.Soc Sci Med 1992;35: 1003–1014.
Google Scholar - Ware JE Jr, Snow KK, Kosinski M, Gandek B.SF-36 Health Survey Manual and Interpretation Guide. Boston: New England Medical Center, 1993.
Google Scholar - Sadura A, Pater J, Osoba D, et al. Quality-of-life assessment: Patient compliance with questionnaire completion.J Natl Cancer Inst 1992;84: 1023–1026.
Google Scholar - Begg CB, Carbone PP, Elson PJ, Zelen M. Participation of community hospitals in clinical trials. Analysis of five years of experience in the Eastern Cooperative Oncology Group.New Engl J Med 1982;306: 1076–1080.
Google Scholar - Meadows AT, Kramer S, Hopson R, et al. Survival in childhood acute lymphocytic leukaemia: effect of protocol and place of treatment.Cancer Invest 1983;1: 49–55.
Google Scholar - Stiller CA, Draper GJ. Treatment centre size, entry to trials, and survival in acute lymphoblastic leukaemia.Arch Dis Child 1989;64: 657–661.
Google Scholar - Karjalainen S, Palva I. Do treatment protocols improve end results? A study of survival of patients with multiple myeloma in Finland.Br Med J 1989;299: 1069–1072.
Google Scholar - Stiller CA. Centralised treatment, entry to trials and survival.Br J Cancer 1994;70: 352–362.
Google Scholar - Bailey KR. Generalizing the results of randomized clinical trials.Control Clin Trials 1994;15: 15–23.
Google Scholar